Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2021 - 2028
This report can be delivered to the clients within Immediate
Biosimulation Market Growth & Trends
The global biosimulation market size is anticipated to reach USD 6.83 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.9% from 2021 to 2028. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.
The need for drug discovery and development amidst the prevalence of acute and chronic diseases has resulted in an increase in the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing the overall costs.
Arise in drug relapse rates, drug resistance cases, and limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications, such as drug development and drug discovery.
The COVID-19 pandemic also had a significant impact on the market. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in the COVID-19 research. As of November 2020, the company declared that its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by the governments of the affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.
Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.
Biosimulation Market Report Highlights
Biosimulation Market Growth & Trends
The global biosimulation market size is anticipated to reach USD 6.83 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.9% from 2021 to 2028. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.
The need for drug discovery and development amidst the prevalence of acute and chronic diseases has resulted in an increase in the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing the overall costs.
Arise in drug relapse rates, drug resistance cases, and limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications, such as drug development and drug discovery.
The COVID-19 pandemic also had a significant impact on the market. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in the COVID-19 research. As of November 2020, the company declared that its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by the governments of the affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.
Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.
Biosimulation Market Report Highlights
- In terms of product, software dominated the market in 2020. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and target drug identification
- By application, the drug development segment accounted for the largest share in 2020
- Based on end use, pharmaceutical and biotechnology companies dominated the market in 2020 due to increasing strategic initiatives
- North America grabbed the largest share in 2020. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure is expected to drive the North American market over the forecast period
- Asia Pacific is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective
1.8.2 Objective
1.8.3 Objective
1.8.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Biosimulation Market Summary
CHAPTER 3 BIOSIMULATION MARKET VARIABLES, TRENDS & SCOPE
3.1 Biosimulation Market Segmentation and Scope
3.2 Biosimulation Market Dynamics
3.2.1 Market driver analysis
3.2.2 Impact analysis
3.2.2.1 Increasing adoption of Physiologically Based Pharmacokinetic modeling in the regulatory approval process of drugs
3.2.2.2 Growing number of relapse cases due to increasing drug resistance
3.2.2.3 Rising Technological advancements
3.2.2.4 Increasing need to reduce drug discovery and development costs
3.2.2.5 Accelerating formulation development and saving costly studies
3.2.2.6 Increasing investments in the life sciences industry
3.2.2.7 Increasing use of personalized medicine
3.2.3 Market restraint analysis
3.2.4 Impact analysis
3.2.4.1 Lack of standardization
3.2.4.2 Shortage of skilled professionals
3.2.4.3 Intellectual property protection and public policy issues
3.3 Penetration and Growth Prospect Mapping, 2020
3.4 Pricing Analysis
3.5 Biosimulation Market Analysis Tools: Porters
3.5.1 Bargaining power of Suppliers: Low
3.5.2 Bargaining power of Buyers: Moderate
3.5.3 Threat of Substitutes: Low
3.5.4 Threat of New Entrants: High
3.5.5 Competitive Rivalry: High
3.6 SWOT Analysis by Factors (Political & Legal, Economic, and Technological)
3.6.1 Political/Legal Landscape
3.6.2 Economic Landscape
3.6.3 Technology Landscape
CHAPTER 4 BIOSIMULATION MARKET: IMPACT OF COVID-19
4.1 Impact of Covid-19 on the Biosimulation Market
4.1.1 Current And Future Impact Analysis
4.1.2 Impact of covid-19 on market players
4.1.3 Disease Prevalence Analysis
CHAPTER 5 BIOSIMULATION MARKET: SEGMENT ANALYSIS, BY PRODUCT, 2016 - 2028 (USD MILLION)
5.1 Definition and Scope
5.2 Product Market Share Analysis, 2020 & 2028
5.3 Biosimulation Market, by Product, 2016 to 2028
5.4 Software
5.4.1 software market, 2016-2028 (USD Million)
5.5 Services
5.5.1 Services market, 2016-2028 (USD Million)
5.5.2 In-house Services
5.5.2.1 In-house Services market, 2016 - 2028 (USD Million)
5.5.3 Contract Services
5.5.3.1 Contract Services market, 2016 - 2028 (USD Million)
CHAPTER 6 BIOSIMULATION MARKET: SEGMENT ANALYSIS, BY APPLICATION, 2016 - 2028 (USD MILLION)
6.1 Definition and Scope
6.2 Application Market Share Analysis, 2020 & 2028
6.3 Biosimulation Market, by Application, 2016 to 2028
6.4 Drug Development
6.4.1 Drug development market, 2016 - 2028 (USD Million)
6.5 Drug Discovery
6.5.1 Drug Discovery market, 2016 - 2028 (USD Million)
6.6 Others
6.6.1 Others market, 2016 - 2028 (USD Million)
CHAPTER 7 BIOSIMULATION MARKET: SEGMENT ANALYSIS, BY END USE, 2016 - 2028 (USD MILLION)
7.1 Definition and Scope
7.2 End-use Market Share Analysis, 2020 & 2028
7.3 Global Biosimulation Market, by End Use, 2016 to 2028
7.4 Pharmaceutical & Biotechnology Companies
7.4.1 Pharmaceutical & biotechnology companies market, 2016 - 2028 (USD Million)
7.5 CROs
7.5.1 CROs market, 2016 - 2028 (USD million)
7.6 Regulatory Authorities
7.6.1 regulatory authorities market, 2016 - 2028 (USD Million)
7.7 Academic Research Institutions
7.7.1 academic research institutions market, 2016 - 2028 (USD million)
CHAPTER 8 BIOSIMULATION MARKET: REGIONAL MARKET ANALYSIS 2016 - 2028 (USD MILLION)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2020 & 2028
8.3 Regional Market Snapshot
8.4 Market Size, & Forecasts, and Trend Analysis, 2016 to 2028
8.5 North America
8.5.1 North America biosimulation Market Share analysis, by country, 2020
8.5.2 U.S.
8.5.2.1 U.S. Biosimulation Market, 2016 - 2028 (USD Million)
8.5.3 Canada
8.5.3.1 Canada Biosimulation Market, 2016 - 2028 (USD Million)
8.6 Europe
8.6.1 Europe Biosimulation Market Share Analysis, By Country, 2020
8.6.2 U.K.
8.6.2.1 U.K.Biosimulation Market, 2016 - 2028 (USD Million)
8.6.3 Germany
8.6.3.1 Germany Biosimulation Market, 2016 - 2028 (USD Million)
8.6.4 France
8.6.4.1 France Biosimulation Market, 2016 - 2028 (USD Million)
8.7 Asia Pacific
8.7.1 Asia Pacific Biosimulation Market Share Analysis, By Country, 2020
8.7.2 Japan
8.7.2.1 Japan Biosimulation Market, 2016 - 2028 (USD Million)
8.7.3 China
8.7.3.1 China Biosimulation Market, 2016 - 2028 (USD million)
8.7.4 India
8.7.4.1 India Biosimulation Market, 2016 - 2028 (USD Million)
8.8 Latin America
8.8.1 Latin America Biosimulation Market Share Analysis, By Country, 2020
8.8.2 Brazil
8.8.2.1 Brazil Biosimulation Market, 2016 - 2028 (USD Million)
8.8.3 Mexico
8.8.3.1 Mexico Biosimulation Market, 2016 - 2028 (USD Million)
8.9 MEA
8.9.1 MEA Biosimulation Market Share Analysis, By Country, 2020
8.9.2 South Africa
8.9.2.1 South Africa Biosimulation Market, 2016 - 2028 (USD Million)
CHAPTER 9 BIOSIMULATION MARKET - COMPETITIVE ANALYSIS
9.1 Strategy Framework
9.2 Market Participant Categorization
9.3 Public Companies
9.3.1 Company market position analysis
9.3.2 Comparative analysis by product category
9.4 Private Companies
9.4.1 List of Private companies
9.4.2 List of Emerging companies in Asia Pacific Region
CHAPTER 10 BIOSIMULATION MARKET - COMPANY PROFILES
10.1 Certara
10.1.1 Company overview
10.1.2 Financial Performance
10.1.3 Product benchmarking
10.1.4 Strategic initiatives
10.2 Simulations Plus
10.2.1 Company overview
10.2.2 Financial performance
10.2.3 Product benchmarking
10.2.4 Strategic initiatives
10.3 DassaultSyst?mes
10.3.1 Company overview
10.3.2 Financial performance
10.3.3 Product benchmarking
10.3.4 Strategic initiatives
10.4 Schr?dinger, Inc.
10.4.1 Company overview
10.4.2 Financial performance
10.4.3 Product benchmarking
10.4.4 Strategic initiatives
10.5 Advanced Chemistry Development
10.5.1 Company overview
10.5.2 Product benchmarking
10.5.3 Strategic initiatives
10.6 Chemical Computing Group ULC
10.6.1 Company overview
10.6.2 Financial performance
10.6.3 Product benchmarking
10.6.4 Strategic initiatives
10.7 PhysiomicsPlc
10.7.1 Company overview
10.7.2 Financial performance
10.7.3 Product benchmarking
10.7.4 Strategic initiatives
10.8 Rosa & Co. LLC.
10.8.1 Company overview
10.8.2 Product benchmarking
10.8.3 Strategic initiatives
10.9 BioSimulation Consulting Inc.
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Service benchmarking
10.10 Genedata AG
10.10.1 Company overview
10.10.2 Financial performance
10.10.3 Product benchmarking
10.10.4 Strategic initiatives
10.11 Instem Group of Companies
10.11.1 Company overview
10.11.2 Financial performance
10.11.3 Product benchmarking
10.11.4 Strategic initiatives
10.12 PPD, Inc. (Evidera)
10.12.1 Company overview
10.12.2 Financial performance
10.12.3 Service benchmarking
10.12.4 Strategic initiatives
10.13 Insilico Biotechnology AG
10.13.1 Company overview
10.13.2 Product benchmarking
10.13.3 Strategic initiatives
10.14 Immunetrics
10.14.1 Company overview
10.14.2 Product benchmarking
CHAPTER 11 KOL COMMENTARY
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective
1.8.2 Objective
1.8.3 Objective
1.8.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Biosimulation Market Summary
CHAPTER 3 BIOSIMULATION MARKET VARIABLES, TRENDS & SCOPE
3.1 Biosimulation Market Segmentation and Scope
3.2 Biosimulation Market Dynamics
3.2.1 Market driver analysis
3.2.2 Impact analysis
3.2.2.1 Increasing adoption of Physiologically Based Pharmacokinetic modeling in the regulatory approval process of drugs
3.2.2.2 Growing number of relapse cases due to increasing drug resistance
3.2.2.3 Rising Technological advancements
3.2.2.4 Increasing need to reduce drug discovery and development costs
3.2.2.5 Accelerating formulation development and saving costly studies
3.2.2.6 Increasing investments in the life sciences industry
3.2.2.7 Increasing use of personalized medicine
3.2.3 Market restraint analysis
3.2.4 Impact analysis
3.2.4.1 Lack of standardization
3.2.4.2 Shortage of skilled professionals
3.2.4.3 Intellectual property protection and public policy issues
3.3 Penetration and Growth Prospect Mapping, 2020
3.4 Pricing Analysis
3.5 Biosimulation Market Analysis Tools: Porters
3.5.1 Bargaining power of Suppliers: Low
3.5.2 Bargaining power of Buyers: Moderate
3.5.3 Threat of Substitutes: Low
3.5.4 Threat of New Entrants: High
3.5.5 Competitive Rivalry: High
3.6 SWOT Analysis by Factors (Political & Legal, Economic, and Technological)
3.6.1 Political/Legal Landscape
3.6.2 Economic Landscape
3.6.3 Technology Landscape
CHAPTER 4 BIOSIMULATION MARKET: IMPACT OF COVID-19
4.1 Impact of Covid-19 on the Biosimulation Market
4.1.1 Current And Future Impact Analysis
4.1.2 Impact of covid-19 on market players
4.1.3 Disease Prevalence Analysis
CHAPTER 5 BIOSIMULATION MARKET: SEGMENT ANALYSIS, BY PRODUCT, 2016 - 2028 (USD MILLION)
5.1 Definition and Scope
5.2 Product Market Share Analysis, 2020 & 2028
5.3 Biosimulation Market, by Product, 2016 to 2028
5.4 Software
5.4.1 software market, 2016-2028 (USD Million)
5.5 Services
5.5.1 Services market, 2016-2028 (USD Million)
5.5.2 In-house Services
5.5.2.1 In-house Services market, 2016 - 2028 (USD Million)
5.5.3 Contract Services
5.5.3.1 Contract Services market, 2016 - 2028 (USD Million)
CHAPTER 6 BIOSIMULATION MARKET: SEGMENT ANALYSIS, BY APPLICATION, 2016 - 2028 (USD MILLION)
6.1 Definition and Scope
6.2 Application Market Share Analysis, 2020 & 2028
6.3 Biosimulation Market, by Application, 2016 to 2028
6.4 Drug Development
6.4.1 Drug development market, 2016 - 2028 (USD Million)
6.5 Drug Discovery
6.5.1 Drug Discovery market, 2016 - 2028 (USD Million)
6.6 Others
6.6.1 Others market, 2016 - 2028 (USD Million)
CHAPTER 7 BIOSIMULATION MARKET: SEGMENT ANALYSIS, BY END USE, 2016 - 2028 (USD MILLION)
7.1 Definition and Scope
7.2 End-use Market Share Analysis, 2020 & 2028
7.3 Global Biosimulation Market, by End Use, 2016 to 2028
7.4 Pharmaceutical & Biotechnology Companies
7.4.1 Pharmaceutical & biotechnology companies market, 2016 - 2028 (USD Million)
7.5 CROs
7.5.1 CROs market, 2016 - 2028 (USD million)
7.6 Regulatory Authorities
7.6.1 regulatory authorities market, 2016 - 2028 (USD Million)
7.7 Academic Research Institutions
7.7.1 academic research institutions market, 2016 - 2028 (USD million)
CHAPTER 8 BIOSIMULATION MARKET: REGIONAL MARKET ANALYSIS 2016 - 2028 (USD MILLION)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2020 & 2028
8.3 Regional Market Snapshot
8.4 Market Size, & Forecasts, and Trend Analysis, 2016 to 2028
8.5 North America
8.5.1 North America biosimulation Market Share analysis, by country, 2020
8.5.2 U.S.
8.5.2.1 U.S. Biosimulation Market, 2016 - 2028 (USD Million)
8.5.3 Canada
8.5.3.1 Canada Biosimulation Market, 2016 - 2028 (USD Million)
8.6 Europe
8.6.1 Europe Biosimulation Market Share Analysis, By Country, 2020
8.6.2 U.K.
8.6.2.1 U.K.Biosimulation Market, 2016 - 2028 (USD Million)
8.6.3 Germany
8.6.3.1 Germany Biosimulation Market, 2016 - 2028 (USD Million)
8.6.4 France
8.6.4.1 France Biosimulation Market, 2016 - 2028 (USD Million)
8.7 Asia Pacific
8.7.1 Asia Pacific Biosimulation Market Share Analysis, By Country, 2020
8.7.2 Japan
8.7.2.1 Japan Biosimulation Market, 2016 - 2028 (USD Million)
8.7.3 China
8.7.3.1 China Biosimulation Market, 2016 - 2028 (USD million)
8.7.4 India
8.7.4.1 India Biosimulation Market, 2016 - 2028 (USD Million)
8.8 Latin America
8.8.1 Latin America Biosimulation Market Share Analysis, By Country, 2020
8.8.2 Brazil
8.8.2.1 Brazil Biosimulation Market, 2016 - 2028 (USD Million)
8.8.3 Mexico
8.8.3.1 Mexico Biosimulation Market, 2016 - 2028 (USD Million)
8.9 MEA
8.9.1 MEA Biosimulation Market Share Analysis, By Country, 2020
8.9.2 South Africa
8.9.2.1 South Africa Biosimulation Market, 2016 - 2028 (USD Million)
CHAPTER 9 BIOSIMULATION MARKET - COMPETITIVE ANALYSIS
9.1 Strategy Framework
9.2 Market Participant Categorization
9.3 Public Companies
9.3.1 Company market position analysis
9.3.2 Comparative analysis by product category
9.4 Private Companies
9.4.1 List of Private companies
9.4.2 List of Emerging companies in Asia Pacific Region
CHAPTER 10 BIOSIMULATION MARKET - COMPANY PROFILES
10.1 Certara
10.1.1 Company overview
10.1.2 Financial Performance
10.1.3 Product benchmarking
10.1.4 Strategic initiatives
10.2 Simulations Plus
10.2.1 Company overview
10.2.2 Financial performance
10.2.3 Product benchmarking
10.2.4 Strategic initiatives
10.3 DassaultSyst?mes
10.3.1 Company overview
10.3.2 Financial performance
10.3.3 Product benchmarking
10.3.4 Strategic initiatives
10.4 Schr?dinger, Inc.
10.4.1 Company overview
10.4.2 Financial performance
10.4.3 Product benchmarking
10.4.4 Strategic initiatives
10.5 Advanced Chemistry Development
10.5.1 Company overview
10.5.2 Product benchmarking
10.5.3 Strategic initiatives
10.6 Chemical Computing Group ULC
10.6.1 Company overview
10.6.2 Financial performance
10.6.3 Product benchmarking
10.6.4 Strategic initiatives
10.7 PhysiomicsPlc
10.7.1 Company overview
10.7.2 Financial performance
10.7.3 Product benchmarking
10.7.4 Strategic initiatives
10.8 Rosa & Co. LLC.
10.8.1 Company overview
10.8.2 Product benchmarking
10.8.3 Strategic initiatives
10.9 BioSimulation Consulting Inc.
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Service benchmarking
10.10 Genedata AG
10.10.1 Company overview
10.10.2 Financial performance
10.10.3 Product benchmarking
10.10.4 Strategic initiatives
10.11 Instem Group of Companies
10.11.1 Company overview
10.11.2 Financial performance
10.11.3 Product benchmarking
10.11.4 Strategic initiatives
10.12 PPD, Inc. (Evidera)
10.12.1 Company overview
10.12.2 Financial performance
10.12.3 Service benchmarking
10.12.4 Strategic initiatives
10.13 Insilico Biotechnology AG
10.13.1 Company overview
10.13.2 Product benchmarking
10.13.3 Strategic initiatives
10.14 Immunetrics
10.14.1 Company overview
10.14.2 Product benchmarking
CHAPTER 11 KOL COMMENTARY
LIST OF TABLES
TABLE 1 List of secondary sources
TABLE 2 List of products for major companies
TABLE 3 List of private companies
TABLE 4 List of emerging companies
TABLE 5North America biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 6 North America biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 7 North America biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 8 North America biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 9 North America biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 10 U.S. biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 11U.S. biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 12 U.S. biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 13 U.S. biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 14 Canada biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 15Canada biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 16 Canada biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 17 Canada biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 18 Europe biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 19 Europe biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 20 Europe biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 21 Europe biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 22 Europe biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 23 Germany biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 24 Germany biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 25 Germany biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 26 Germany biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 27 U.K. biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 28 U.K. biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 29 U.K. biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 30 U.K. biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 31 France biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 32 France biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 33 France biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 34 France biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 35 Asia Pacific biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 36 Asia Pacific biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 37 Asia Pacific biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 38 Asia Pacific biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 39 Asia Pacific biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 40 Japan biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 41 Japan biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 42 Japan biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 43 Japan biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 44 China biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 45 China biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 46 China biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 47 China biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 48 India biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 49 India biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 50 India biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 51 India biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 52 Latin America biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 53 Latin America biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 54 Latin America biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 55 Latin America biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 56 Latin America biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 57 Brazil biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 58 Brazil biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 59 Brazil biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 60 Brazil biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 61 Mexico biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 62 Mexico biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 63 Mexico biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 64 Mexico biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 65 MEA biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 66 MEA biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 67 MEA biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 68 MEA biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 69 MEA biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 70 South Africa biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 71 South Africa biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 72 South Africa biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 73 South Africa biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 1 List of secondary sources
TABLE 2 List of products for major companies
TABLE 3 List of private companies
TABLE 4 List of emerging companies
TABLE 5North America biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 6 North America biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 7 North America biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 8 North America biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 9 North America biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 10 U.S. biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 11U.S. biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 12 U.S. biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 13 U.S. biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 14 Canada biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 15Canada biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 16 Canada biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 17 Canada biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 18 Europe biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 19 Europe biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 20 Europe biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 21 Europe biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 22 Europe biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 23 Germany biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 24 Germany biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 25 Germany biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 26 Germany biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 27 U.K. biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 28 U.K. biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 29 U.K. biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 30 U.K. biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 31 France biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 32 France biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 33 France biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 34 France biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 35 Asia Pacific biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 36 Asia Pacific biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 37 Asia Pacific biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 38 Asia Pacific biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 39 Asia Pacific biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 40 Japan biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 41 Japan biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 42 Japan biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 43 Japan biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 44 China biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 45 China biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 46 China biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 47 China biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 48 India biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 49 India biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 50 India biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 51 India biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 52 Latin America biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 53 Latin America biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 54 Latin America biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 55 Latin America biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 56 Latin America biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 57 Brazil biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 58 Brazil biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 59 Brazil biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 60 Brazil biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 61 Mexico biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 62 Mexico biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 63 Mexico biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 64 Mexico biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 65 MEA biosimulation market, by country, 2016 - 2028 (USD Million)
TABLE 66 MEA biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 67 MEA biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 68 MEA biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 69 MEA biosimulation market, by end use, 2016 - 2028 (USD Million)
TABLE 70 South Africa biosimulation market, by product, 2016 - 2028 (USD Million)
TABLE 71 South Africa biosimulation services market, by type, 2016 - 2028 (USD Million)
TABLE 72 South Africa biosimulation market, by application, 2016 - 2028 (USD Million)
TABLE 73 South Africa biosimulation market, by end use, 2016 - 2028 (USD Million)
LIST OF FIGURES
FIG. 1 Biosimulation market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 Market formulation & validation
FIG. 8 Commodity Flow Analysis
FIG. 9 Biosimulation Market outlook (2020, USD Million)
FIG. 10 Biosimulation market segmentation and scope
FIG. 11 Biosimulation market dynamics analysis
FIG. 12 Biosimulation market driver and restraints impact analysis
FIG. 13 Biosimulation market driver analysis
FIG. 14 Biosimulation market drivers impact analysis
FIG. 15 R&D expenditures by various market players in 2020 (USD Million)
FIG. 16 Biosimulation market restraint impact
FIG. 17 Biosimulation market restraint impact analysis
FIG. 18 Penetration & growth prospect mapping
FIG. 19 COVID-19 new cases in major 35 countries around the world
FIG. 20 Biosimulation market: Product movement analysis
FIG. 21 Biosimulation market product outlook: Key takeaways
FIG. 22 Software market, 2016 - 2028 (USD Million)
FIG. 23 Services market, 2016 - 2028 (USD Million)
FIG. 24 In-house Services market, 2016 - 2028 (USD Million)
FIG. 25 Contract Services market, 2016 - 2028 (USD Million)
FIG. 26 Biosimulation market: Application movement analysis
FIG. 27 Biosimulation market application outlook: Key takeaways
FIG. 28 Drug development market, 2016 - 2028 (USD Million)
FIG. 29 Drug discovery market, 2016 - 2028 (USD Million)
FIG. 30 Others market, 2016 - 2028 (USD Million)
FIG. 31 Biosimulation market: End-use movement analysis
FIG. 32 Biosimulation market end-use outlook: Key takeaways
FIG. 33 Pharmaceutical & biotechnology companies market, 2016 - 2028 (USD Million)
FIG. 34 CROs market, 2016 - 2028 (USD Million)
FIG. 35 Regulatory authorities market, 2016 - 2028 (USD Million)
FIG. 36 Academic research institutions market, 2016 - 2028 (USD Million)
FIG. 37 Regional outlook, 2020 & 2028
FIG. 38 Regional marketplace: Key takeaways
FIG. 39 North America Biosimulation market share, by country, 2020
FIG. 40 U.S. biosimulation market, 2016 - 2028 (USD Million)
FIG. 41 Canada biosimulation market, 2016 - 2028 (USD Million)
FIG. 42 Europe biosimulation market share analysis, by country, 2020
FIG. 43 U.K. Biosimulation market, 2016 - 2028 (USD Million)
FIG. 44 Germany biosimulation market, 2016 - 2028 (USD Million)
FIG. 45 France biosimulation market, 2016 - 2028 (USD Million)
FIG. 46 Asia Pacific biosimulation market share analysis, by country, 2020
FIG. 47 Japan biosimulation market, 2016 - 2028 (USD Million)
FIG. 48 China biosimulation market, 2016 - 2028 (USD Million)
FIG. 49 India biosimulation market, 2016 - 2028 (USD Million)
FIG. 50 Latin America Biosimulation market share analysis, by country, 2020
FIG. 51 Brazil biosimulation market, 2016 - 2028 (USD Million)
FIG. 52 Mexico Biosimulation market, 2016 - 2028 (USD Million)
FIG. 53 MEA biosimulation market share analysis, by country, 2020
FIG. 54 South Africa biosimulation market, 2016 - 2028 (USD Million)
FIG. 55 Strategy framework
FIG. 56 Market participant categorization
FIG. 57 Biosimulation: Heat Map Analysis
FIG. 58 Biosimulation market: Application wise product ranking
FIG. 1 Biosimulation market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 Market formulation & validation
FIG. 8 Commodity Flow Analysis
FIG. 9 Biosimulation Market outlook (2020, USD Million)
FIG. 10 Biosimulation market segmentation and scope
FIG. 11 Biosimulation market dynamics analysis
FIG. 12 Biosimulation market driver and restraints impact analysis
FIG. 13 Biosimulation market driver analysis
FIG. 14 Biosimulation market drivers impact analysis
FIG. 15 R&D expenditures by various market players in 2020 (USD Million)
FIG. 16 Biosimulation market restraint impact
FIG. 17 Biosimulation market restraint impact analysis
FIG. 18 Penetration & growth prospect mapping
FIG. 19 COVID-19 new cases in major 35 countries around the world
FIG. 20 Biosimulation market: Product movement analysis
FIG. 21 Biosimulation market product outlook: Key takeaways
FIG. 22 Software market, 2016 - 2028 (USD Million)
FIG. 23 Services market, 2016 - 2028 (USD Million)
FIG. 24 In-house Services market, 2016 - 2028 (USD Million)
FIG. 25 Contract Services market, 2016 - 2028 (USD Million)
FIG. 26 Biosimulation market: Application movement analysis
FIG. 27 Biosimulation market application outlook: Key takeaways
FIG. 28 Drug development market, 2016 - 2028 (USD Million)
FIG. 29 Drug discovery market, 2016 - 2028 (USD Million)
FIG. 30 Others market, 2016 - 2028 (USD Million)
FIG. 31 Biosimulation market: End-use movement analysis
FIG. 32 Biosimulation market end-use outlook: Key takeaways
FIG. 33 Pharmaceutical & biotechnology companies market, 2016 - 2028 (USD Million)
FIG. 34 CROs market, 2016 - 2028 (USD Million)
FIG. 35 Regulatory authorities market, 2016 - 2028 (USD Million)
FIG. 36 Academic research institutions market, 2016 - 2028 (USD Million)
FIG. 37 Regional outlook, 2020 & 2028
FIG. 38 Regional marketplace: Key takeaways
FIG. 39 North America Biosimulation market share, by country, 2020
FIG. 40 U.S. biosimulation market, 2016 - 2028 (USD Million)
FIG. 41 Canada biosimulation market, 2016 - 2028 (USD Million)
FIG. 42 Europe biosimulation market share analysis, by country, 2020
FIG. 43 U.K. Biosimulation market, 2016 - 2028 (USD Million)
FIG. 44 Germany biosimulation market, 2016 - 2028 (USD Million)
FIG. 45 France biosimulation market, 2016 - 2028 (USD Million)
FIG. 46 Asia Pacific biosimulation market share analysis, by country, 2020
FIG. 47 Japan biosimulation market, 2016 - 2028 (USD Million)
FIG. 48 China biosimulation market, 2016 - 2028 (USD Million)
FIG. 49 India biosimulation market, 2016 - 2028 (USD Million)
FIG. 50 Latin America Biosimulation market share analysis, by country, 2020
FIG. 51 Brazil biosimulation market, 2016 - 2028 (USD Million)
FIG. 52 Mexico Biosimulation market, 2016 - 2028 (USD Million)
FIG. 53 MEA biosimulation market share analysis, by country, 2020
FIG. 54 South Africa biosimulation market, 2016 - 2028 (USD Million)
FIG. 55 Strategy framework
FIG. 56 Market participant categorization
FIG. 57 Biosimulation: Heat Map Analysis
FIG. 58 Biosimulation market: Application wise product ranking
